Changes in metabolic markers [ total alkaline phosphatase ( AP ) , bone-specific AP and fibroblast growth factor-23 ( FGF-23 ) ] and the proportion of patients in each treatment group who achieved an iPTH level of 150-300 pg/mL during Weeks 8 , 16 and 21-28 as a composite value were evaluated .